AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027.
The medical technology company’s shares rose 1.33% in premarket trading following the earnings release.
Fourth-Quarter Revenue Exceeds Expectations
For the quarter ended 31 May 2026, AngioDynamics reported an adjusted loss of $0.07 per share, outperforming analysts’ expectations of a $0.09 per-share loss.
Revenue increased 8.0% year-over-year to $86.6 million, comfortably ahead of the consensus forecast of $80.2 million.
Growth was led by the company’s Med Tech division, where revenue climbed 16.7% to $41.8 million, extending its streak of double-digit growth to seven consecutive quarters.
Fiscal 2027 Revenue Guidance Impresses
Looking ahead, AngioDynamics forecast adjusted earnings per share of between a loss of $0.29 and $0.24 for fiscal 2027. While the midpoint of this range falls below the analyst consensus estimate of a $0.20 loss per share, the company’s revenue guidance was considerably stronger than expected.
Management projected fiscal 2027 revenue of between $336 million and $341 million, well above the consensus forecast of $314 million. The midpoint of $338.5 million exceeded market expectations by approximately $24.5 million.
“Full-year Med Tech growth of more than 18% reflects the continued progress of our strategic transformation, as our innovative platform technologies across cardiology and interventional oncology took share in large, fast-growing global markets,” said Jim Clemmer, President and Chief Executive Officer.
Profitability and Balance Sheet Continue to Improve
For the full 2026 fiscal year, AngioDynamics reported net sales of $320.2 million, representing annual growth of 9.4%.
Adjusted EBITDA improved significantly to $13.2 million from $7.6 million in the previous fiscal year, reflecting stronger operational performance.
The company finished the year with $53.9 million in cash and no outstanding debt, providing financial flexibility to support future growth initiatives.
Med Tech Segment Remains Key Growth Driver
AngioDynamics expects Med Tech revenue to grow between 12% and 15% during fiscal 2027, while sales in its Med Device business are projected to remain broadly unchanged.
Management also forecasts gross margins of between 54% and 55%, alongside adjusted EBITDA in the range of $13.0 million to $16.0 million as it continues executing its transformation strategy.
AngioDynamics stock price
